Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that finasteride significantly improved hirsutism scores in women over 12 months and was well-tolerated with no serious side effects.

In this study, topical tofacitinib significantly promoted hair regrowth in mice, outpacing both minoxidil and controls over 21 days, with findings suggesting increased VEGF levels and decreased inflammation as possible mechanisms.

Hair loss can happen after severe H1N1 flu but usually grows back in 4 months.

This retrospective study evaluated the use of tofacitinib as an induction therapy for severe alopecia areata and found it promising and comparable to the standard oral mini-pulse treatment, though pulse steroids may be considered if tofacitinib response is inadequate.

According to this study, systemic retinoids, specifically oral isotretinoin and acitretin, were more effective than finasteride in stabilizing the frontal hairline in female patients with frontal fibrosing alopecia, achieving treatment goals in over 70% of cases.

In this study, the researchers found no superiority of combining 308-nm excimer laser with intralesional corticosteroid over corticosteroid alone for treating frontal fibrosing alopecia, and reported side effects such as erythema and postinflammatory hyperpigmentation in both treatment groups.

The article in Dermatologic Therapy discusses clinical experiences with using tofacitinib to treat alopecia areata in 63 patients, but no specific results are reported in the abstract.

In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.

This study observed that frontal fibrosing alopecia in postmenopausal women involves selective follicular inflammation, and finasteride treatment may slow disease progression, suggesting a potential androgen-related component.

This randomized clinical trial compared bimatoprost 0.03% solution and mometasone furoate 0.1% cream for treating alopecia areata in 60 patients, finding that mometasone furoate led to better hair regrowth, while both treatments showed significant effectiveness.

This study reported no significant improvement in patients with frontal fibrosing alopecia treated with various therapeutic agents, highlighting the need for more evidence-based treatments, especially in those with active disease.

This retrospective study found that oral tofacitinib significantly reduced the severity of alopecia areata in children, achieving over a 50% reduction in hair loss severity, though relapse occurred during treatment tapering, and mild adverse effects were noted.

This review outlines the main findings from clinical trials on teriflunomide's efficacy and safety for relapsing multiple sclerosis, noting clinical considerations and exploring its mechanisms based on various studies.

Tofacitinib might be used to treat hair loss.

This article includes no new results; it discusses ongoing treatment approaches for frontal fibrosing alopecia and lichen planopilaris.

5% minoxidil foam helps women with thinning hair.

Dutasteride, fesoterodine, and finasteride help older patients with urinary issues.

In this study, the authors developed a medicated face mask using electrospun fibers to deliver the active compound Eflornithine hydrochloride for managing hirsutism. The mask showed promising drug release characteristics, a high safety profile, and reduced hair growth in mice.

This study found that topical finasteride and flutamide both significantly reduced sebaceous gland growth and decreased prostatic weights in hamsters, indicating systemic effects despite local application.

In this study, bimatoprost solution showed better results than corticosteroid in terms of rapidity, percentage of hair regrowth, and side effects for treating scalp alopecia areata.

This study found that topical eflornithine HCl 13.9% cream effectively reduced facial hair in women, with a favorable safety profile.

This study reported that while no effective treatment exists for frontal fibrosing alopecia, oral 5-alpha-reductase inhibitors showed the most promise, inducing a good clinical response in 45% of patients.

This study found that combining cyproterone acetate with topical eflornithine was a safe and effective treatment for facial hirsutism in women.